

**Supplementary Table 1. Associations of diabetes with mortality among participants with pancreatic ductal adenocarcinoma (PDAC, N=437) in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.**

	No history of diabetes HR (95% CI)	Positive History of diabetes HR (95% CI)	P-value
<b>Overall (N=437)</b>			
Model 1 <sup>a</sup>	1.00 (ref)	1.47 (1.09-2.00)	0.01
Model 1 <sup>b</sup>	1.00 (ref)	1.55 (1.13-2.12)	0.01
<b>Excluding cases diagnosed within 3 years of enrollment (N=346)</b>			
Model 1 <sup>a</sup>	1.00 (ref)	1.41 (1.01-1.97)	0.05
Model 1 <sup>b</sup>	1.00 (ref)	1.43 (1.01-2.03)	0.04
<b>Among Males (N=234)</b>			
Model 1 <sup>a</sup>	1.00 (ref)	1.54 (1.03-2.30)	0.03
Model 1 <sup>b</sup>	1.00 (ref)	1.81 (1.20-2.75)	0.01
<b>Among Females (N=203)</b>			
Model 1 <sup>a</sup>	1.00 (ref)	1.46 (0.91-2.35)	0.12
Model 1 <sup>b</sup>	1.00 (ref)	1.35 (0.79-2.31)	0.27
<b>Localized (N=86)</b>			
Model 1 <sup>b</sup>	1.00 (ref)	3.02 (1.45-6.28)	<0.01
<b>Locally advanced (N=112)</b>			
Model 1 <sup>b</sup>	1.00 (ref)	1.24 (0.62-2.51)	0.55
<b>Metastatic (N=239)</b>			
Model 1 <sup>b</sup>	1.00 (ref)	1.42 (0.93-2.18)	0.11

<sup>a</sup>Adjusted for age and stage

<sup>b</sup>Adjusted for age, sex, body mass index (BMI), race, smoking and stage. Sex and stage not adjusted for in analyses stratified on these variables.

